AstraZeneca, along with many of its big pharma peers, has struggled to deliver new drugs in recent years. In the hopes of turning the company around, its Chief Executive Officer Pascal Soriot recently shuffled the scientific management and promoted Menelas Pangalos to head up the discovery and early-stage development of small molecules. Pangalos has been with AstraZeneca since 2010 and has previously worked at Pfizer as head of neuroscience research and development (R&D), as well as at Wyeth and GlaxoSmithKline. Part of AstraZeneca's salvation may be in becoming less risk averse, he tells Asher Mullard.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Menelas Pangalos. Nat Rev Drug Discov 12, 418 (2013). https://doi.org/10.1038/nrd4044
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4044
